In:
International Journal of Cancer, Wiley, Vol. 144, No. 3 ( 2019-02), p. 569-581
Abstract:
What's new? While epidermal growth factor ligands amphiregulin (AREG) and epiregulin (EREG) are well‐established predictive biomarkers, the regulation of their gene expression in colorectal cancer (CRC) is poorly understood. This study suggests that gene body methylation differentially controls AREG and EREG gene expression, with a complex interplay between DNA methylation‐controlled intragenic regions within the AREG gene and the AREG promoter. Furthermore, gene methylation assessment alone may not be sufficient as an improved predictive marker in combination with KRAS. Patients with KRAS/NRASwt, low AREG expression, and high AREG methylation may potentially benefit from demethylation treatment to increase AREG expression prior to anti‐EGFR therapies.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Bookmarklink